格隆汇2月6日丨药明康德(603259.SH)在投资者互动平台表示，Chemistry 42属于另一家生物科技公司， 和药明康德无关。公司历来不自行开发新药，也没有用AI来开发新药。 ...

Core Viewpoint - Morgan Stanley has reduced its stake in WuXi AppTec (02359) by 798,119 shares at a price of HKD 109.1481 per share, totaling approximately HKD 87.1132 million, resulting in a new holding of about 35.2451 million shares, representing 6.90% of the company [1] Summary by Category - **Share Reduction** - Morgan Stanley sold 798,119 shares of WuXi AppTec [1] - The sale price was HKD 109.1481 per share [1] - The total amount from the sale was approximately HKD 87.1132 million [1] - **Current Holdings** - After the reduction, Morgan Stanley's remaining shares in WuXi AppTec are approximately 35.2451 million [1] - The new ownership percentage is 6.90% [1]

Core Viewpoint - Morgan Stanley has reduced its stake in WuXi AppTec (02359) by selling 798,119 shares at a price of HKD 109.1481 per share, totaling approximately HKD 87.1132 million, resulting in a new holding of about 35.2451 million shares, representing 6.90% of the company [1] Group 1 - Morgan Stanley sold 798,119 shares of WuXi AppTec on February 3 [1] - The selling price per share was HKD 109.1481, leading to a total transaction value of approximately HKD 87.1132 million [1] - After the sale, Morgan Stanley's remaining shares in WuXi AppTec are approximately 35.2451 million, which constitutes a 6.90% ownership stake [1]

证券日报网讯 2月6日，药明康德（603259）在互动平台回答投资者提问时表示，2025年前三季度，公 司来自欧洲客户收入为38.4亿元，占公司持续经营业务收入的12%。 ...

（文章来源：证券日报） 证券日报网讯 2月6日，药明康德在互动平台回答投资者提问时表示，公司历来不自行开发新药，也没 有用AI来开发新药。 ...

文章还表示，金元顺安医疗健康、同泰大健康主题、华泰柏瑞远见智选等，成立以来跌幅也都在50%以 上。 陈铭杰2016年6月加入金元顺安基金管理有限公司，历任专户投资部投资经理等。2023年10月27日起任基金 经理，管理经验尚不足3年。 张海东曾任中原农业保险股份有限公司资产管理部总经理、中国人民健康保险股份有限公司投资管理部处 长、渤海证券北京西外大街营业部担任交易部经理兼客服务部经理、大通证券北京营业部担任柜台主管、 分析师，2025年5月加入金元顺安基金管理有限公司，从2025年8月25日担任基金经理。 2025年4季度的前十大重仓股为三生国健、百利天恒、迪哲医药、百普赛斯（301080）、百济神州、艾力 斯、药明康德（603259）、恒瑞医药（600276）、迈威生物、博瑞医药。 中国经济网北京2月6日讯 2月4日，智通财经发布《2021年成立的基金还拿不回本？五成亏损 问题究竟出在 哪？》一文。文中称，2021年大量主动权益基金密集成立，时间一晃过去四年多，A股重新站在4000点上 方，但2021年那一批在牛市尾声发车的基金却并没有集体扬眉吐气。智通财经记者以2021年成立并仍存续 的667只主动权益 ...

Group 1 - The top three companies with the highest short positions are COSCO Shipping Holdings (01919), Dongfang Electric (01072), and Vanke Enterprises (02202), with short ratios of 18.70%, 16.91%, and 16.66% respectively [1][2] - The companies with the largest increase in short positions are Ganfeng Lithium (01772), Sanhua Intelligent Control (02050), and CATL (03750), with increases of 2.04%, 1.63%, and 1.51% respectively [1][2] - The companies with the largest decrease in short positions are Kanglong Chemical (03759), Aneng Logistics (09956), and Changfei Optical Fiber (06869), with decreases of -1.71%, -1.68%, and -1.01% respectively [1][3] Group 2 - The latest short position data shows that COSCO Shipping Holdings has 516 million shares short, up from 511 million shares previously, while Dongfang Electric has 68.99 million shares short, down from 70.83 million shares [2] - The companies with the largest short position increases include Ganfeng Lithium, which rose from 7.67% to 9.70%, and Sanhua Intelligent Control, which increased from 5.76% to 7.39% [2] - The companies with the largest short position decreases include Kanglong Chemical, which fell from 5.35% to 3.64%, and Aneng Logistics, which dropped from 2.68% to 1.00% [3][4]

Investment Rating - The report indicates a positive outlook for the pharmaceutical industry, with a recommendation for investment based on favorable fundamentals [17]. Core Insights - The Hong Kong pharmaceutical sector outperformed the Hang Seng Index in January, with the Hang Seng Healthcare Index rising by 8.6%, exceeding the index by 1.7 percentage points. This was driven by several factors, including profit warnings from CXO sector companies, advancements in internet healthcare, and supportive policies from the National Healthcare Security Administration (NHSA) for high-quality surgical robots [1][7]. - The NHSA has issued guidelines to support the pricing of high-quality surgical robots, allowing for premium pricing based on their advanced capabilities and precision in complex surgeries [3][15]. - The State Drug Administration continues to back the development of high-quality innovative drugs, emphasizing clinical value and providing market exclusivity for certain medications, including those for rare diseases and pediatric use [2][14]. Summary by Sections Industry Performance - The pharmaceutical industry in Hong Kong showed strong performance in January, with significant contributions from the CXO sector and internet healthcare companies like JD Health and Ark Health, which reported positive earnings forecasts [1][7]. Policy Support - Recent revisions to the Drug Administration Law emphasize support for innovative drug development, including streamlined approval processes and enhanced regulatory oversight to ensure drug safety and quality [2][14]. - The NHSA's new pricing guidelines for surgical robots aim to incentivize the use of advanced medical technologies, potentially leading to increased revenue for companies involved in this sector [3][15]. Company Recommendations - China Biologic Products (1177 HK) is expected to see double-digit sales growth by 2025, bolstered by its acquisition of Haogiya Biotech, which specializes in small nucleic acid drugs [4][16]. - WuXi AppTec (2359 HK) and WuXi Biologics (2269 HK) have also shown promising earnings forecasts, indicating a recovery in demand within the CXO sector [4][16]. - The report highlights the potential of leading medical AI platform companies, such as Insilico Medicine (3696 HK), which has secured multiple overseas licensing deals, reflecting high industry recognition for its capabilities in enhancing pharmaceutical R&D efficiency [4][16].

Core Viewpoint - The Hong Kong pharmaceutical sector is experiencing a significant rebound, particularly in innovative drugs, with several companies reporting strong earnings forecasts and positive growth trends [1][8]. Group 1: Innovative Drug Sector - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw a rise of nearly 2% after opening lower, indicating strong investor interest [1][8]. - Innovent Biologics (诺诚健华) led the gains with a rise of over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1][8]. - Other companies like Rongchang Biopharmaceutical and CanSino Biologics also reported profitability, with net profit growth exceeding 100% year-on-year [1][8]. Group 2: Medical Sector - The medical sector is also showing positive momentum, with AI healthcare and CXO-related stocks active; Ark Health (方舟健客) led with a 4.71% increase [3][10]. - Ark Health forecasts a profit of 7 to 10 million yuan for 2025, indicating a turnaround from previous losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3][10]. - Among the 10 component stocks of the Hong Kong Stock Connect Medical ETF (159137) that disclosed earnings forecasts, 9 are expected to be profitable, with several companies anticipating net profit growth of over 100% [3][10]. Group 3: Market Trends and Investment Opportunities - Despite the positive earnings outlook, the recent performance of the pharmaceutical sector has diverged from these fundamentals, with the Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing four consecutive weeks of declines [5][12]. - The current market conditions may present a favorable opportunity for accumulation in the Hong Kong pharmaceutical sector, particularly through ETFs, which offer higher efficiency and flexibility [5][12]. - Investors are encouraged to consider the Hong Kong Stock Connect Innovative Drug ETF (520880) and its associated funds for a comprehensive exposure to innovative drug companies, with the top ten holdings accounting for over 73% of the portfolio [6][12].

Group 1: Market Overview - The Hong Kong pharmaceutical sector showed significant recovery on February 6, with innovative drugs experiencing a rebound, particularly the Hong Kong Stock Connect Innovative Drug ETF (520880), which rose by nearly 2% after opening in the red [1] - Notable stocks included Nocera Biopharma, which surged over 12%, projecting revenues of 2.37 billion yuan for 2025, a year-on-year increase of approximately 134%, and an expected net profit of around 630 million yuan, marking its first profit [1] Group 2: Company Performance - Rongchang Biopharma and CanSino Biologics also reported profitability, with both companies forecasting net profit growth exceeding 100% year-on-year [1] - Ark Health announced a profit forecast of 7 to 10 million yuan for 2025, indicating a turnaround from losses, and raised approximately 144.3 million HKD to accelerate the development of its AI-driven chronic disease management platform [3] - Among the 10 component stocks of the Hong Kong Stock Connect Medical ETF (159137) that disclosed earnings forecasts, 9 are expected to report profits, with several companies like Zhaoyan New Drug, MicroPort Medical, and WuXi AppTec anticipating net profit growth of over 100% [3]